Status:
UNKNOWN
Spironolactone for Paroxysmal Atrial Fibrillation
Lead Sponsor:
Taichung Veterans General Hospital
Conditions:
Atrial Fibrillation
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
To determine whether or not spironolactone can prevent or delay the occurrence of atrial fibrillation.
Detailed Description
To determine whether or not adding spironolactone can prevent or delay the occurrence of paroxysmal atrial fibrillation in patients who have received propafenone treatment.
Eligibility Criteria
Inclusion
- Inclusion criteria:
- 18 to 80 Y/O,
- Paroxysmal AF.
- Exclusion criteria:
- GPT\>100 IU/L or tota bilirubin \>2 mg/dl;
- Creatinine \> 2 mg/dl;
- Serum potassium \>= 5 mM;
- Serum sodium \<=130 mM;
- Uric acid \> 10 mg/dl。
Exclusion
Key Trial Info
Start Date :
March 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2011
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00689598
Start Date
March 1 2008
End Date
March 1 2011
Last Update
June 5 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Taichung General Hospital
Taichung, Taiwan, 40705